NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Oxford Cancer Biomarkers

Oxford Cancer Biomarkers

Private
OxfordHealthcare & Life Scienceshttps://oxfordbio.com/

Last Round

VC Round

Apr 3, 2023

Est. Valuation

$15.67M

Total Funding Raised

$6.47M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Oxford Cancer Biomarkers is a biotechnology company that develops and commercializes AI-driven, precision cancer diagnostic tests.

Sector

Healthcare & Life Sciences

Verticals

Precision Medicine, Biotechnology, Medical AI, Healthcare Analytics, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Application

Keywords

cancer biomarkersprecision oncologypersonalized medicinediagnostic testscolorectal cancer diagnosticspharmacogenomicsdigital pathologyAI diagnosticsPGx testingchemotherapy toxicitycancer recurrence riskgenetic testingclinical decision supportmedical AI

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Oxford Cancer Biomarkers Comps

Public and private peers based on sector, stage, and business model.

Oxford Cancer Biomarkers comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Oxford Cancer Biomarkers Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundApr 3, 2023
GrantMar 3, 2023
VC RoundDec 14, 2015
Series AJan 18, 2012

Oxford Cancer Biomarkers Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 15, 2026

    Monthly visitors grew 50% MoM, reaching 1.3K.

  • Apr 20, 2026

    Monthly visitors grew 333% MoM, from 204 to 883.

Oxford Cancer Biomarkers Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Oxford Cancer Biomarkers Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Oxford Cancer Biomarkers's valuation, stock price, and market status.

Firmographic Details

HeadquartersOxford
Employee Range8
Year Founded2012
Last FundingApr 3, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.